Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response.

@article{SalazardePablo2022SystematicRA,
  title={Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response.},
  author={Gonzalo Salazar de Pablo and Carolina Pastor Jord{\'a} and Julio Vaquerizo-Serrano and Carmen Moreno and Anna Cabras and Celso Arango and Patricia Hern{\'a}ndez and Jeremy Veenstra-VanderWeele and Emily Simonoff and Paolo Fusar-Poli and Paramala J Santosh and Samuele Cortese and Mara Parellada},
  journal={Journal of the American Academy of Child and Adolescent Psychiatry},
  year={2022}
}
1 Citations
Editorial: Weighing Benefits and Risks While Treating Irritability and Emotional Dysregulation in Autism.
  • Manpreet K. Singh
  • Medicine
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 2022

References

SHOWING 1-10 OF 100 REFERENCES
Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis
TLDR
Risperidone and aripiprazole were found to be the most effective medications in reducing ABC-I in youth with ASD, but a few other compounds also showed significant efficacy with fewer potential side effects and adverse reactions in single studies.
Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis
TLDR
Placebo response in ASD was substantial and predicted by design- and participant-related factors, which could inform the design of future trials in order to improve the detection of efficacy in core symptoms.
Atypical Antipsychotics for Irritability in Pediatric Autism: A Systematic Review and Network Meta-Analysis.
TLDR
Risperidone and aripiprazole were the two best drugs, with comparable efficacy and safety in pediatric ASD patients, and these two medications could be beneficial in improving irritability in these patients.
Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
  • R. Rodrigues, M. Lai, S. Ameis
  • Psychology, Medicine
    Journal of child psychology and psychiatry, and allied disciplines
  • 2020
TLDR
Direct pooled evidence supports the efficacy and tolerability of methylphenidate or atomoxetine for treatment of ADHD symptoms in children and youth with ASD.
Efficacy of Interventions Based on Applied Behavior Analysis for Autism Spectrum Disorder: A Meta-Analysis
Objective To systematically evaluate evidence for the use of interventions based on appied behavior analysis (ABA) to manage various symptoms of children with autism spectrum disorder (ASD). Methods
A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder.
TLDR
In this study, there was no statistically significant difference between aripiprazole and placebo in time to relapse during maintenance therapy, however, the HR and NNT suggest some patients will benefit from maintenance treatment.
Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability.
TLDR
Risperidone can be individually titrated to optimal dosage for excellent response in the majority of children and is better with greater symptom severity, while weight gain is not necessary for ris peridone benefit and may even detract from it.
Placebo and nocebo responses in randomised, controlled trials of medications for ADHD: a systematic review and meta-analysis
TLDR
Although ADHD medications are superior to placebo, and placebo treatment in clinical practice is not feasible, clinicians should attempt to incorporate factors associated with placebo effects into clinical care.
A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder
TLDR
5-week of riluzole treatment was well tolerated, but had no significant effect on the target symptoms, and there were no statistically significant findings for the overall treatment effect, the treatment effect by week within period of the study, or a cross-over effect across the periods of theStudy.
...
...